证券代码：688222 证券简称：成都先导 公告编号：2023-034 成都先导药物开发股份有限公司 第二届董事会第十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 成都先导药物开发股份有限公司（以下简称"公司"）第二届董事会第十一次 会议于 2023 年 8 月 21 日在公司会议室以现场结合通讯表决方式召开，会议通知 已于 2023 年 8 月 11 日以书面方式送达全体董事。本次会议应出席董事 9 名，实 际出席董事 9 名，公司董事会秘书、监事列席本次会议，会议由董事长 JIN LI（李 进）先生召集并主持。本次会议的召集和召开程序符合有关法律、行政法规、部 门规章、规范性文件和《公司章程》的规定，会议决议合法、有效。 二、董事会会议审议情况 全体董事对本次董事会会议议案进行了审议，经表决形成如下决议： （一）审议通过《关于公司 2023 年半年度报告及其摘要的议案》 具体内容详见公司于同日刊登在上海证券交易所网站（www.sse.com.cn）的 《成都先导药物开发股份有 ...

成都先导药物开发股份有限公司监事会 关于公司 2023 年限制性股票激励计划（草案）的 核查意见 成都先导药物开发股份有限公司（以下简称"公司"）监事会依据《中华人 民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管 理办法》"）、《上海证券交易所科创板股票上市规则》（以下简称"《上市规 则》"）、《科创板上市公司自律监管指南第 4 号——股权激励信息披露》等相 关法律、法规及规范性文件和《成都先导药物开发股份有限公司章程》（以下 简称"《公司章程》"）的有关规定，对公司《2023 年限制性股票激励计划（草 案）》（以下简称"《激励计划（草案）》"）进行了核查，发表核查意见如下： 综上所述，我们一致同意公司实行 2023 年限制性股票激励计划。 成都先导药物开发股份有限公司监事会 2023 年 8 月 21 日 2 1、公司不存在《管理办法》等法律、法规规定的禁止实施股权激励计划的 情形，包括：（1）最近一个会计年度财务会计报告被注册会计师出具否定意见 或者无法表示意见的审计报告；（2）最近一个会计年度财务报告内部控制 ...

一、 召开会议的基本情况 召开日期时间：2023 年 9 月 7 日 14 点 30 分 召开地点：四川省成都市双流区剑南大道南段 1166 号希尔顿花园酒店 6 楼 天府厅 （五） 网络投票的系统、起止日期和投票时间。 证券代码：688222 证券简称：成都先导 公告编号：2023-038 成都先导药物开发股份有限公司 关于召开 2023 年第一次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2023 年 9 月 7 日 至 2023 年 9 月 7 日 股东大会召开日期：2023年9月7日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （一） 股东大会类型和届次 2023 年第一次临时股东大会 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 采用上海证券交易所网络投票系统，通过交易系统 ...

成都先导药物开发股份有限公司 2023 年限制性股票激励计划激励对象名单 | 序 | | | | 获授的限制 | 占授予限制 | 占本激励计划 | | --- | --- | --- | --- | --- | --- | --- | | 号 | 姓名 | 国籍 | 职务 | 性股票数量 | 性股票总数 | 公告日股本总 | | | | | | (万股) | 的比例 | 额的比例 | | | 一、高级管理人员、核心技术人员 | | | | | | | 1 | 刘观赛 | 中国 | 副总经理、研发化学 | 3 | 2.422% | 0.007% | | | | | 中心副总裁 | | | | | 2 | 窦登峰 | 中国 | 副总经理、先导化合 | 0.6 | 0.484% | 0.001% | | | | | 物发现中心副总裁 | | | | | 3 | 刘红哿 | 中国 | 财务负责人、首席财 | 1 | 0.807% | 0.002% | | | | | 务官 | | | | | | | 小计 | | 4.6 | 3.714% | 0.011% | | | 二、其他激励对象（134 | | 人） | 11 ...

成都先导药物开发股份有限公司 证券代码：688222 证券简称：成都先导 公告编号：2023-024 关于召开 2022 年度暨 2023 年第一季度业绩说明会 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 成都先导药物开发股份有限公司（以下简称"公司"）已于 2023 年 4 月 29 日在上海证券交易所网站（www.sse.com.cn）披露公司 2022 年年度报告及 2023 年第一季度报告，为便于广大投资者更全面深入 地了解公司 2022 年度及 2023 年第一季度经营成果、财务状况，公司 计划于 2023 年 5 月 23 日下午 14:00-15:00 举行 2022 年度暨 2023 年 第一季度业绩说明会，就投资者关心的问题进行交流。 会议召开时间：2023 年 5 月 23 日(星期二) 下午 14:00-15:00 会议召开地点： 上海证券 交易所上证路演中心（ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 一、说明会类型 本次 ...

Financial Performance - The company reported a total revenue of HKD 1.5 billion for the fiscal year 2022, representing a year-over-year increase of 15%[14]. - The company achieved operating revenue of CNY 329.65 million in 2022, representing a year-on-year increase of 5.98%[24]. - The net profit attributable to shareholders was CNY 25.27 million, a decrease of 60.14% compared to the previous year[24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 12.50 million, down 46.36% year-on-year[24]. - The net cash flow from operating activities was CNY 52.74 million, an increase of 21.25% compared to the previous year[24]. - The company reported a significant decrease of 67.48% in profits derived from government subsidies, amounting to CNY 16.13 million[131]. - The company achieved a comprehensive gross margin of 47.67%, an increase of 0.65 percentage points from the previous year[136]. - The gross margin improved to 60%, up from 55% in the previous year, due to cost optimization strategies[14]. Research and Development - Investment in R&D increased by 25% in 2022, focusing on mRNA drug development and high-throughput screening technologies[15]. - The R&D investment accounted for 26.50% of operating revenue, an increase of 2.81 percentage points year-on-year[25]. - The company is currently upgrading its next-generation DEL technology and building a nucleic acid new drug research platform and targeted protein degradation platform, leading to increased R&D expenditures[26]. - The company has established a comprehensive drug optimization system covering various technical aspects, enabling the discovery and development of new molecules up to the clinical trial application stage[78]. - The company has a research team of nearly 80 professionals covering various fields, enhancing its drug development capabilities[73]. - The total R&D investment for the year was approximately ¥87.36 million, representing an 18.58% increase from the previous year, and accounting for 26.50% of the company's revenue[97]. - The company has developed a DNA-encoded compound library (DEL) with over 12 trillion small molecules, making it the largest known physical small molecule compound library globally[105]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by 2025[14]. - The company is exploring potential acquisitions to strengthen its portfolio, with a budget of up to HKD 500 million allocated for this purpose[14]. - The company aims to enhance its core technologies, particularly in DEL technology, to improve compound library diversity and screening success rates[169]. - The company is actively forming a domestic business development team and launching customized services and products, including a one-stop new drug development and transfer service[175]. - The company aims to increase its domestic and international marketing outlets to enhance the depth and breadth of its marketing services, ultimately forming a global marketing service network[175]. Corporate Governance and Management - The company has not proposed any special arrangements for corporate governance in the reporting period[8]. - The company has undergone several management changes, including the appointment of new directors and supervisors in 2022[196]. - The company continues to focus on strengthening its board composition and governance practices through regular elections and appointments[196]. - The company appointed a new CFO, Liu Honghe, on April 27, 2023, replacing the previous financial head, Hu Chunyan, who will continue as the financial director in Chengdu[200]. - The company’s board of directors is actively involved in management changes to enhance operational efficiency[199]. Risks and Challenges - The company has highlighted various risks in its operations, including uncertainties related to government subsidies and the performance of acquired subsidiaries[5]. - The company is cautious about increasing R&D investments in ongoing projects due to rising labor costs and potential market challenges[4]. - The company faces risks related to new drug development failures, particularly as it targets new molecular entities with higher failure rates compared to modified or generic drugs[120]. - The company is exposed to the risk of technological obsolescence in drug discovery methods, as the market evolves rapidly with various screening technologies[120]. - The acquisition of UK company Vernalis may pose management risks due to cultural and operational integration challenges[121]. Product Development and Innovation - The company is developing proprietary nucleic acid drug delivery systems based on its established coding/decoding system and diverse molecular library[74]. - The company has established partnerships with global biopharmaceutical companies and research institutions, enhancing its collaborative research capabilities[34]. - The company aims to become a leading innovative biopharmaceutical enterprise, focusing on small molecule and nucleic acid drug discovery and optimization[38]. - The company has synthesized over 1.2 trillion diverse and drug-like DNA-encoded compounds based on more than 6,000 different scaffold structures, demonstrating its capability in identifying lead compounds for known and emerging biological targets[39]. - The company is advancing four projects in Phase I clinical trials and has two projects ready for IND submission, demonstrating a robust pipeline of new drug candidates[36]. User Engagement and Market Performance - User data showed an increase in active users by 20%, reaching a total of 2 million users by the end of 2022[14]. - The company provided a future outlook, projecting a revenue growth of 10% for 2023, driven by new product launches and market expansion[14]. - The company reported a revenue of $1.5 billion for the fiscal year 2022, representing a 15% increase year-over-year[193]. - User data showed a growth of 25% in active users, reaching 10 million by the end of 2022[193]. - The company completed a strategic acquisition of a biotech firm for $100 million, enhancing its product pipeline[193].

[First Quarter Report 2023](index=1&type=section&id=2023%20First%20Quarter%20Report) [Important Notes](index=1&type=section&id=Important%20Notes) The board guarantees the report's authenticity, and the financial statements are unaudited - The Board of Directors, Supervisory Committee, and senior management guarantee the authenticity, accuracy, and completeness of the quarterly report content[2](index=2&type=chunk) - The first quarter financial statements are **unaudited**[3](index=3&type=chunk) [Key Financial Data](index=1&type=section&id=I.%20Key%20Financial%20Data) This section outlines Q1 2023 financial data, non-recurring items, and explanations for key metric changes [Key Accounting Data and Financial Indicators](index=1&type=section&id=(I)Key%20Accounting%20Data%20and%20Financial%20Indicators) Q1 revenue slightly decreased, net profit was negative, but operating cash flow turned positive amid higher R&D spending Key Accounting Data and Financial Indicators | Item | Current Period Amount (CNY) | YoY Change (%) | | :--- | :--- | :--- | | Operating Revenue | 69,572,588.38 | -3.99 | | Net Profit Attributable to Shareholders | -9,393,596.88 | N/A | | Net Profit Attributable to Shareholders (Excluding Non-recurring Items) | -10,320,244.79 | N/A | | Net Cash Flow from Operating Activities | 19,779,297.51 | N/A | | Basic Earnings Per Share (CNY/Share) | -0.02 | N/A | | Diluted Earnings Per Share (CNY/Share) | -0.02 | N/A | | Total R&D Investment | 20,648,543.13 | 21.28 | | R&D Investment as a Percentage of Operating Revenue (%) | 29.68 | Increased by 6.19 percentage points | Key Balance Sheet Items | Item | End of Current Period (CNY) | End of Prior Year (CNY) | Change from Prior Year-End (%) | | :--- | :--- | :--- | :--- | | Total Assets | 1,656,729,729.98 | 1,668,990,981.13 | -0.73 | | Equity Attributable to Shareholders | 1,290,622,121.35 | 1,302,512,123.62 | -0.91 | [Non-recurring Profit and Loss Items and Amounts](index=2&type=section&id=(II)Non-recurring%20Profit%20and%20Loss%20Items%20and%20Amounts) Non-recurring P&L totaled CNY 926,647.91, primarily driven by government subsidies | Item | Current Period Amount (CNY) | Notes | | :--- | :--- | :--- | | Gain/Loss on Disposal of Non-current Assets | -3,141.88 | | | Government Grants Included in Current Profit or Loss | 1,097,679.95 | | | Other Non-operating Income and Expenses | 426.87 | | | Less: Income Tax Impact | 168,317.03 | | | Total | 926,647.91 | | [Changes and Reasons for Key Accounting Data and Financial Indicators](index=2&type=section&id=(III)Changes%20and%20Reasons%20for%20Key%20Accounting%20Data%20and%20Financial%20Indicators) Increased R&D spending, positive operating cash flow from collections, and a wider net loss due to lower subsidies are noted - **The ratio of R&D investment to operating revenue increased by 6.19 percentage points**, mainly due to continuous upgrades of the DEL screening technology platform[5](index=5&type=chunk) - **Net cash flow from operating activities was CNY 19.78 million**, a significant turnaround from -CNY 5.80 million in the prior year period, driven by a substantial increase in sales collections[5](index=5&type=chunk) - **Net loss attributable to shareholders was -CNY 9.39 million**, compared to -CNY 7.09 million in the prior year period, primarily due to a decrease in government subsidies received[5](index=5&type=chunk) [Shareholder Information](index=3&type=section&id=II.%20Shareholder%20Information) This section details shareholder count, top ten shareholder holdings, and their relationships as of the report date [Total Number of Common Shareholders and Top Ten Shareholders' Holdings](index=3&type=section&id=(I)Total%20Number%20of%20Common%20Shareholders%20and%20Top%20Ten%20Shareholders'%20Holdings) The company had 11,921 common shareholders, with JIN LI (李进) being the largest shareholder at 20.43% - The total number of common shareholders at the end of the reporting period was **11,921**[7](index=7&type=chunk) Top 10 Shareholders | Shareholder Name | Shareholder Type | Number of Shares Held (Shares) | Shareholding Ratio (%) | Number of Restricted Shares Held (Shares) | | :--- | :--- | :--- | :--- | :--- | | JIN LI(李进) | Foreign Individual | 81,876,948 | 20.43 | 81,876,948 | | Lhasa Economic and Technological Development Zone Huabo Medical Devices Co., Ltd. | Domestic Non-state-owned Corporation | 54,785,953 | 13.67 | 0 | | Chengdu Juzhi Kechuang Biotechnology Partnership (Limited Partnership) | Other | 38,651,163 | 9.65 | 38,651,163 | | Anji Dongfang Jiayu Enterprise Management Partnership (Limited Partnership) | Other | 33,665,721 | 8.40 | 0 | | Shenzhen Juntian Investment Enterprise (Limited Partnership) | Other | 20,132,314 | 5.02 | 0 | | Zhang Chi | Domestic Individual | 14,540,984 | 3.63 | 0 | | JUMBO KINDNESS LIMITED | Foreign Corporation | 13,815,543 | 3.45 | 0 | | Sichuan Development Securities Investment Fund Management Co., Ltd. - Chuanfa Select No. 3 Private Equity Fund | Other | 13,677,070 | 3.41 | 0 | | Hangzhou Dinghui New Trend Equity Investment Partnership (Limited Partnership) | Other | 12,243,377 | 3.06 | 0 | | Juntian Venture Capital Co., Ltd. | Domestic Non-state-owned Corporation | 11,931,448 | 2.98 | 0 | [Top 10 Unrestricted Shareholders' Holdings](index=4&type=section&id=Top%2010%20Unrestricted%20Shareholders'%20Holdings) Lhasa Economic and Technological Development Zone Huabo Medical Devices Co., Ltd. was the largest unrestricted shareholder | Shareholder Name | Number of Unrestricted Shares Held (Shares) | Share Type and Quantity (Shares) | | :--- | :--- | :--- | | Lhasa Economic and Technological Development Zone Huabo Medical Devices Co., Ltd. | 54,785,953 | RMB Ordinary Share 54,785,953 | | Anji Dongfang Jiayu Enterprise Management Partnership (Limited Partnership) | 33,665,721 | RMB Ordinary Share 33,665,721 | | Shenzhen Juntian Investment Enterprise (Limited Partnership) | 20,132,314 | RMB Ordinary Share 20,132,314 | | Zhang Chi | 14,540,984 | RMB Ordinary Share 14,540,984 | | JUMBO KINDNESS LIMITED | 13,815,543 | RMB Ordinary Share 13,815,543 | | Sichuan Development Securities Investment Fund Management Co., Ltd. - Chuanfa Select No. 3 Private Equity Fund | 13,677,070 | RMB Ordinary Share 13,677,070 | | Hangzhou Dinghui New Trend Equity Investment Partnership (Limited Partnership) | 12,243,377 | RMB Ordinary Share 12,243,377 | | Juntian Venture Capital Co., Ltd. | 11,931,448 | RMB Ordinary Share 11,931,448 | | Chongqing Boyi Xintian Equity Investment Fund Partnership (Limited Partnership) | 9,507,637 | RMB Ordinary Share 9,507,637 | | Long Star Growth Group Limited | 8,866,101 | RMB Ordinary Share 8,866,101 | [Description of Related Parties or Concerted Actions](index=5&type=section&id=Description%20of%20Related%20Parties%20or%20Concerted%20Actions) The report discloses concerted action relationships among several key shareholders - JIN LI (李进), as the executive partner of Chengdu Juzhi Kechuang Biotechnology Partnership (Limited Partnership), is a party acting in concert with Juzhi Kechuang[9](index=9&type=chunk) - Shenzhen Juntian Investment Enterprise (Limited Partnership) and Juntian Venture Capital Co., Ltd. are parties acting in concert[9](index=9&type=chunk) - Hangzhou Dinghui New Trend Equity Investment Partnership (Limited Partnership) and Long Star Growth Group Limited are parties acting in concert[9](index=9&type=chunk) [Other Matters](index=5&type=section&id=III.%20Other%20Matters) No other significant operational matters requiring investor attention were disclosed for the reporting period - The company did not disclose other significant operational matters requiring investor attention during the reporting period[10](index=10&type=chunk) [Quarterly Financial Statements](index=5&type=section&id=IV.%20Quarterly%20Financial%20Statements) This section presents the unaudited consolidated balance sheet, income statement, and cash flow statement for Q1 2023 [Audit Opinion Type](index=5&type=section&id=(I)Audit%20Opinion%20Type) The quarterly financial statements have not been audited - The quarterly financial statements are **unaudited**[10](index=10&type=chunk) [Consolidated Balance Sheet](index=5&type=section&id=Consolidated%20Balance%20Sheet) Total assets slightly decreased to CNY 1.66 billion, with shifts in current and non-current asset composition | Item | March 31, 2023 (CNY) | December 31, 2022 (CNY) | | :--- | :--- | :--- | | Cash and Cash Equivalents | 270,092,919.60 | 358,002,603.58 | | Trading Financial Assets | 622,425,916.67 | 542,049,777.78 | | Accounts Receivable | 73,097,113.83 | 96,904,322.40 | | Inventories | 29,281,806.09 | 25,269,024.97 | | Total Current Assets | 1,114,551,645.87 | 1,145,184,180.57 | | Intangible Assets | 69,294,219.06 | 51,874,893.82 | | Long-term Deferred Expenses | 49,137,297.51 | 46,328,167.04 | | Total Non-current Assets | 542,178,084.11 | 523,806,800.56 | | Total Assets | 1,656,729,729.98 | 1,668,990,981.13 | | Total Liabilities | 341,278,376.32 | 341,748,374.51 | | Total Equity Attributable to Parent Company | 1,290,622,121.35 | 1,302,512,123.62 | [Consolidated Income Statement](index=8&type=section&id=Consolidated%20Income%20Statement) The company reported a net loss of CNY 9.39 million on revenue of CNY 69.57 million in Q1 2023 | Item | Q1 2023 (CNY) | Q1 2022 (CNY) | | :--- | :--- | :--- | | Total Operating Revenue | 69,572,588.38 | 72,465,855.95 | | Total Operating Costs | 87,582,724.31 | 91,164,576.82 | | R&D Expenses | 20,648,543.13 | 17,024,869.24 | | Operating Profit | -11,549,642.89 | -9,685,546.89 | | Total Profit | -11,552,357.90 | -8,392,138.60 | | Net Profit | -9,294,847.57 | -7,088,441.60 | | Net Profit Attributable to Parent Company Shareholders | -9,393,596.88 | -7,088,441.60 | | Basic Earnings Per Share (CNY/Share) | -0.02 | -0.02 | - **R&D expenses increased by 21.28% YoY** to CNY 20.65 million[15](index=15&type=chunk) - The net after-tax amount of other comprehensive income was **-CNY 3.25 million**, a narrowed loss compared to -CNY 12.91 million in the prior year period[16](index=16&type=chunk) [Consolidated Cash Flow Statement](index=10&type=section&id=Consolidated%20Cash%20Flow%20Statement) Operating cash flow turned positive to CNY 19.78 million, while investing activities resulted in a significant cash outflow | Item | Q1 2023 (CNY) | Q1 2022 (CNY) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 19,779,297.51 | -5,800,253.79 | | Net Cash Flow from Investing Activities | -103,309,465.02 | 2,490,146.44 | | Net Cash Flow from Financing Activities | -2,903,899.50 | -15,544,681.65 | | Net Increase in Cash and Cash Equivalents | -89,305,620.50 | -19,955,814.13 | | Cash and Cash Equivalents at End of Period | 267,058,822.40 | 325,529,048.72 | - **Cash received from sales of goods and rendering of services increased by 48.56% YoY** to CNY 98.36 million[18](index=18&type=chunk) - **Cash paid for the acquisition of fixed assets, intangible assets, and other long-term assets increased significantly** from CNY 4.77 million to CNY 26.72 million[18](index=18&type=chunk)

证券代码：688222 证券简称：成都先导 成都先导药物开发股份有限公司 投资者关系活动记录表 （2022 年 4 月） | --- | --- | --- | |-------------------------|----------------------------------------------------------|-------------------------------------------------------------------------------------------------------| | 投资者关系活动 \n类别 | 特定对象调研 \n□媒体采访 \n□新闻发布会 \n□现场参观 | 分析师会议 \n 业绩说明会 \n 路演活动 | | | 其他 （电话会议） | | | | 2022 年 4 月 7 日 | 15:30-16:30 （国金医药 创新药前沿技术 | | | 系列专题：成都先导从 | DNA 编码到核酸药物研发专家会） : | | | | 国金医药、淡水泉、长盛基金、贺腾投资、博时基金、华 | | | | 泰自营、永安国富、高毅资产、玖鹏资产 ...

证券代码：688222 证券简称：成都先导 成都先导药物开发股份有限公司 投资者关系活动记录表 （2022 年 5 月） | --- | --- | --- | |-----------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------| | | □特定对象调研 \n□媒体采访 | 分析师会议 \n 业绩说明会 | | 投资者关系活动 类别 | □新闻发布会 | 路演活动 | | | □现场参观 | | | | 其他 （电话会议） | | | 参与单位名称及 | 2022 年 5 月 20 | 日（业绩说明会） : 通过"上证路演中心"网络平台参与公司 2021 年度业绩说 | | 人员姓名 | 明会的投资者 | | | 时间 | 2022 年 5 月 20 日 | | | 参会方式 | | 上海证券交易所上证路演中心（网址 ...

证券代码：688222 证券简称：成都先导 成都先导药物开发股份有限公司 投资者关系活动记录表 （2022 年 6 月） | --- | --- | --- | |----------------|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------| | | 特定对象调研 | 分析师会议 | | 投资者关系活动 | □媒体采访 | 业绩说明会 | | 类别 | □新闻发布会 | 路演活动 | | | □现场参观 | | | | 其他 （电话会议） | | | | 2022 年 6 月 14 日 | 15:00-16:00 （特定对象调研电话会议） : | | | | 方正证券、易方达基金、凯石基金、中信资管、方正合生、 | | | 汐泰投资、金百镕投资、健顺投资 | | | 参与单位名称及 | 2022 年 ...